Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas 
Welcome,         Profile    Billing    Logout  
 11 Diseases   1 Trial   1 Trial   409 News 


«123456»
  • ||||||||||  Efficacy of Semaglutide by Background Sodium-Glucose Cotransporter 2 Inhibitor: A Post Hoc Analysis of SUSTAIN 9 () -  Feb 2, 2020 - Abstract #QDEM42020QDEM_42;    
    In this post hoc analysis, SUSTAIN 9 data were analysed by background SGLT2is (empagliflozin, canagliflozin, dapagliflozin or other [ipragliflozin, luseogliflozin and tofogliflozin; drugs available only in Japan])... InsubjectswithT2Dalready receivinganSGLT2i,semaglutide generallyresultedin superior HbA1c and body weightreductions vs. placebo,regardless of background SGLT2i Therapy.
  • ||||||||||  Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Retrospective data, Review, Journal:  Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. (Pubmed Central) -  Jan 30, 2020   
    However, wide CIs for many comparisons suggest limited precision, and therefore clinically important adverse events cannot be ruled out. Dapagliflozin, appears to independently increase the risk of UTI, although the mechanism for this intraclass variation in risk is unclear.
  • ||||||||||  Steglatro (ertugliflozin) / Pfizer, Merck (MSD), Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Review, Journal:  Natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes. (Pubmed Central) -  Dec 28, 2019   
    In addition, other natural product-derived compounds have been investigated for their ability to improve blood glucose control. The present review summarizes the natural products with SGLT2 inhibitory activity, and the synthetic compounds obtained from them, and discusses their application for the treatment of diabetes.
  • ||||||||||  Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    [VIRTUAL] EFFECT OF SGLT2 INHIBITORS ON LIPID PARAMETERS: A META-ANALYSIS OF 30 RANDOMIZED CLINICAL TRIALS AND 10,246 PATIENTS (eAbstract Virtual Hall) -  Dec 22, 2019 - Abstract #ACC2020ACC_7362;    
    A random-effects model (DerSimonian-Laird method) and the generic inverse variance method were used to derive pooled estimates across studies 30 RCT involving 10246 patients were included (canagliflozin in 13 studies, dapagliflozin in 11, empagliflozin in 4, ipragliflozin in 1, and remogliflozin in 1). Chronic treatment with SGLT2i reduces TG levels while slightly increasing both HDL-C and LDL-C levels
  • ||||||||||  Steglatro (ertugliflozin) / Pfizer, Merck (MSD), Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Review, Journal:  Mineral and Electrolyte Disorders With SGLT2i Therapy. (Pubmed Central) -  Nov 29, 2019   
    JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.
  • ||||||||||  Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
    Clinical, Journal:  A reduced M1-like/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition. (Pubmed Central) -  Nov 28, 2019   
    We previously reported that, in obese mice, the sodium-glucose cotransporter 2 inhibitor ipragliflozin (Ipra) promoted the expansion of the epididymal adipose tissue (Epi) with increase of serum ketone body concentration...Ketone body β-hydroxybutyrate suppressed Il15 gene induction in M1-polarized cultured macrophages, and a ketogenic diet reproduced the adipose tissue expansion without deteriorating systemic glucose metabolism in mice. Our data indicate that the phenotypic switch of ATMs could mediate healthy adipose tissue expansion by treatment with Ipra, and it may offer new insights into the pathophysiological mechanisms of adipose tissue expansion.
  • ||||||||||  Steglatro (ertugliflozin) / Pfizer, Merck (MSD), Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Use of SGLT-2 inhibitors in patients with T2DM and kidney disease: An Asian perspective and expert recommendations (Poster Area) -  Nov 20, 2019 - Abstract #IDF2019IDF_1347;    
    Given its consistent benefits on the CV and renal outcomes, SGLT-2i represent an essential therapy for the management of Asian T2DM patients with kidney or CV disease or those with multiple risk factors. Based on the currently available evidence and experts’ clinical opinion, a series of recommendations have been developed for the use of SGLT-2i in this population.
  • ||||||||||  Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
    Preclinical, Journal:  Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice. (Pubmed Central) -  Oct 30, 2019   
    Even low-dose ipragliflozin reduced renal cortical hypoxia and abnormal hemodynamics in early diabetic nephropathy. In addition to these effects, high-dose ipragliflozin exerted renoprotective effects by reducing oxidative stress in tubular epithelia and glomerular podocytes.
  • ||||||||||  Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
    The Diuretic Actions of SGLT2 Inhibitors and Loop Diuretics Induce Different Compensating Mechanisms (Exhibit Hall, Walter E. Washington Convention Center) -  Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_2856;    
    Background We recently reported that SGLT2 inhibitor ipragliflozin (Ipra) exhibits a sustained diuretic and natriuretic tone that activates compensatory increases in fluid and food intake, and solute-free water reabsorption to stabilize body fluid volume (Am J Physiol Renal Physiol 2018, ASN Kidney Week 2018)...Methods Sprague-Dawley rats were treated by oral gavage with vehicle (Veh), loop diuretic furosemide (FR) [50mg/kg] or Ipra [5mg/kg] (n= 4-8) in metabolic cages for 1 week...The loop diuretic decreased both parameters with the impaired solute-free water reabsorption unexpectedly being associated with a lack of compensatory increases in vasopressin secretion and fluid intake. Funding Government Support - Non-U.S.
  • ||||||||||  Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
    The Study on the Transition of Renal Function of SGLT2 Inhibitors for Type 2 Diabetes with Moderate to Severe Renal Impairment (Exhibit Hall, Walter E. Washington Convention Center) -  Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_2674;    
    On the other hand, no adverse events related to SGLT2i other than RRT were observed during the period. Conclusion The administration of SGLT2i to T2DM with moderate to severe renal impairment can strongly and safely suppress the decline of eGFR, and can lead to enormous medical economic benefits by extending dialysis induction.
  • ||||||||||  Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
    Trial completion date, Trial primary completion date:  Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin (clinicaltrials.gov) -  Oct 8, 2019   
    P3,  N=170, Recruiting, 
    Conclusion The administration of SGLT2i to T2DM with moderate to severe renal impairment can strongly and safely suppress the decline of eGFR, and can lead to enormous medical economic benefits by extending dialysis induction. Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
    SIRT1 SIGNALING MAY BE INVOLVED IN ATTENUATION OF LIVER STEATOSIS BY THE SGLT2 INHIBITOR IPRAGLIFLOZIN (Hynes Convention Center, Hall B) -  Sep 29, 2019 - Abstract #AASLD2019AASLD_999;    
    Hepatic SIRT1 signaling may be involved in attenuating hepatic steatosis by the ipragliflozin treatment. Further evaluation is much needed to clarify the mechanism of activation of hepatic SIRT1 signaling possibly through PGC-1α/PPARα-FGF21 after treatment with the SGLT2 inhibitor ipragliflozin.
  • ||||||||||  Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
    Clinical, Journal:  Lower Cardiovascular Risk Associated with SGLT-2i in >400,000 Patients: The CVD-REAL 2 Study. (Pubmed Central) -  Aug 15, 2019   
    P=N/A
    A reduction in cardiac sympathetic nerve hyperactivity by an SGLT2 inhibitor might be one of the mechanisms of its cardio-protective effect, but clinical studies need to be conducted to verify this finding. In this large, international study of patients with T2D from the Asia-Pacific, Middle East and North America, initiation of SGLT-2i was associated with a lower risk of CV events, across a broad range of outcomes and patient characteristics.
  • ||||||||||  Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
    Preclinical, Journal:  Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat. (Pubmed Central) -  Jul 11, 2019   
    ...Here we first compared the effect of the SGLT2 inhibitor ipragliflozin (Ipra, 0.01% in diet for 8 wk) and vehicle (Veh) in Spontaneously Diabetic Torii rat, a nonobese type 2 diabetic model, and nondiabetic Sprague-Dawley rats...In conclusion, SGLT2 inhibition induces a sustained diuretic and natriuretic tone. Homeostatic mechanisms are activated to stabilize body fluid volume, including compensatory increases in fluid and food intake.
  • ||||||||||  Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
    Preclinical, Journal:  In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor. (Pubmed Central) -  Jul 11, 2019   
    Ipragliflozin, but not phlorizin, inhibited hSGLT2 in a wash-resistant manner, suggesting that binding of ipragliflozin to hSGLT2 was persistent. These data demonstrate that ipragliflozin is a competitive inhibitor of SGLT2, has high selectivity for SGLT2 over not only SGLT1 but also other SGLT family members, and binds persistently to hSGLT2.
  • ||||||||||  Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
    Preclinical, Journal:  Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice. (Pubmed Central) -  Jul 6, 2019   
    ...Second, the cumulative effect of chronic SGLT2 inhibition by ipragliflozin and 30% calorie restriction, either of which lowered blood glucose to a similar extent, on renal glucose metabolism was evaluated...Tubulointerstitial macrophage infiltration and fibrosis were ameliorated only by calorie restriction, which may have been due to autophagy activation, which was observed only with calorie restriction. Thus, chronic SGLT2 inhibition is efficient in normalizing the levels of accumulated tricarboxylic acid cycle intermediates and increased oxidative stress in the kidneys of diabetic mice.
  • ||||||||||  Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
    Trial completion, Trial completion date:  HARUKAS: Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes (clinicaltrials.gov) -  Apr 17, 2018   
    P=N/A,  N=231, Completed, 
    Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Oct 2018 --> Dec 2019 Active, not recruiting --> Completed | Trial completion date: Sep 2017 --> Feb 2018
  • ||||||||||  Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
    Enrollment closed:  Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy (clinicaltrials.gov) -  Jun 19, 2017   
    P4,  N=103, Active, not recruiting, 
    Recruiting --> Completed | Initiation date: Jan 2016 --> Apr 2016 | Trial primary completion date: Jan 2019 --> Jun 2017 Recruiting --> Active, not recruiting